CCCCC4 Therapeutics, Inc.
$3.05+34% 1Y
$3.05
$1.7152 weeks$4.67
Latest close: below its 200-day averageOct 23, 2026what changed →
Is the price fair?
What CCCC's price assumes
C4 Therapeutics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 17.4× revenue.
17.4
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 2.47
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 2.47
- EV / EBIToperating margin −319%: the multiple describes the denominator
- not meaningful
- Market capitalisation123.0 million shares, counted Jul 31, 2026
- $375M
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.